My Learning - touchHAEMATOLOGY

Sign Up to Receive Your Personalised Learning Resources

Jon Edelson Clinical Expertise into Business success

JOURNALS

Turning your Clinical Expertise into Business Success

Start Learning

CONFERENCE HUB

Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024

touchCONGRESS

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

CE/CME ACCREDITED

JOURNALS

#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?

JOURNALS

Positive phase III VERIFY study results for rusfertide in polycythemia vera

JOURNALS

Greatest Hits of 2024

JOURNALS

#EHA2025: AnitoCell shows promise in RRMM with 97% ORR in iMMagine-1

JOURNALS

Dr Elena Crisà on how precision medicine is revolutionalizing haematology: touchHAEMATOLOGY Future Leader 2025

touchFOCUS

Looking to the future in the treatment of steroid-refractory chronic GvHD

CE/CME ACCREDITED

JOURNALS

#ASH24: Must-know updates in multiple myeloma

CONFERENCE HUB

Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs

CONFERENCE HUB

Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024

touchCONGRESS

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

CE/CME ACCREDITED

JOURNALS

#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?

JOURNALS

Positive phase III VERIFY study results for rusfertide in polycythemia vera

JOURNALS

Greatest Hits of 2024

JOURNALS

#EHA2025: AnitoCell shows promise in RRMM with 97% ORR in iMMagine-1

JOURNALS

Dr Elena Crisà on how precision medicine is revolutionalizing haematology: touchHAEMATOLOGY Future Leader 2025

touchFOCUS

Looking to the future in the treatment of steroid-refractory chronic GvHD

CE/CME ACCREDITED

JOURNALS

#ASH24: Must-know updates in multiple myeloma

CONFERENCE HUB

Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs

CONFERENCE HUB

Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024

touchCONGRESS

Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024

CE/CME ACCREDITED

JOURNALS

#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?

JOURNALS

Positive phase III VERIFY study results for rusfertide in polycythemia vera

Sign up to view Favourites, Keep Notes and Track CME Credits

Favourites

What’s new in primary ITP? Key updates from ASH 2024

View

#ASH24: The countdown is on!

View

Coming soon! touchHAEMATOLOGY Future Leaders 2025

View

#EHA25: INCA33989 shows promise as disease-modifying therapy for essential thrombocythemia

View

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

View

EHA 2025: The countdown is on!

View

#ASCO25: Dr Miguel-Angel Perales unveils the CAR T Vision Coalition

View

DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia

View

#EHA2025: Are menin inhibitors the next standard of care for high-risk AML?

View

Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025

View

Journal articles and more to your inbox

Get the latest clinical insights from touchHAEMATOLOGY

Feedback

Feedback

Sign Up to Receive Your Personalised Learning Resources

Start Learning

Sign up to view Favourites, Keep Notes and Track CME Credits

Favourites

Journal articles and more to your inbox

Listen on the go

Share this activity

Feedback

Feedback

Feedback

Sign Up to Receive Your Personalised Learning Resources

Start Learning

Sign up to view Favourites, Keep Notes and Track CME Credits

Favourites

Journal articles and more to your inbox

Log into your Touch Account

Register now for FREE Access

Sign up with an Email

This Functionality is forMembers Only

This Functionality is for
Members Only